CRISPR Gene Editing Newsletter
Issue #16December 22, 20257 studies

CRISPR base editors hit 1000x resistance breakthrough while new muscle therapy outperforms viral delivery

This week brought major advances in CRISPR precision and delivery. Researchers evolved super-resistant gene editors, cracked muscle cell targeting challenges, and discovered that an anti-CRISPR "inhibitor" actually enhances editing accuracy.

🧬 Scientists evolve CRISPR editors with 1000x resistance to their strongest inhibitor

  • Researchers used a new system called CRISPR-MACE to continuously evolve Cas9 editors directly in human cells, generating variants with nearly 1000-fold enhanced resistance to AcrIIA4 (the most potent known Cas9 inhibitor)

  • The same gatekeeper mutation emerged first across independent evolution campaigns, enabling subsequent adaptive changes along two different functional axes of Cas9 activity

  • The platform combines virus-based continuous evolution with anti-CRISPR proteins to create tunable selection pressure, allowing researchers to engineer Cas9 variants with both increased and decreased DNA binding capacity

Why it matters: This approach solves a key limitation in CRISPR engineering—most optimization happens in bacteria, which fails to capture the complex requirements of human cells where the editors actually need to work.

Key Findings

🎯 Lipid nanoparticles outperform viral vectors for muscle gene therapy

  • Lipid nanoparticle (LNP) delivery of CRISPR components induced more efficient gene editing in muscle satellite cells than adeno-associated virus (AAV) vectors in a Duchenne muscular dystrophy mouse model

  • LNP-CRISPR showed greater resistance to repeated muscle injuries compared to AAV-CRISPR, indicating successful editing of the regenerative satellite cell population

  • The approach worked through both intramuscular and intravenous administration routes

💡 This could provide a safer, non-viral platform for durable muscle therapies that maintain effectiveness even as muscles undergo injury and repair.
🥈 Top 2% journal 🔗 Cell reports Journal Article 🗓️ Dec 18

🔄 Anti-CRISPR "inhibitor" actually enhances prime editing precision

  • The anti-CRISPR protein AcrIIA5 enhanced prime editing activity by up to 8.2-fold while markedly reducing unwanted insertions and deletions

  • AcrIIA5 worked across various prime editing approaches (PE2, PE3, PE4, PE5, and PE6) and different edit types (substitutions, insertions, deletions)

  • The protein appears to inhibit re-nicking activity of the prime editing complex rather than enhancing the core editing machinery

💡 A known "inhibitor" can paradoxically act as an "enhancer," providing an unexpected strategy to optimize gene editing specificity.
🥈 Top 2% journal 🔗 Nature communications Journal Article 🗓️ Dec 18

👁️ Base editing restores vision protein in patient retinal organoids

  • Adenine base editing successfully corrected a pathogenic variation in the AIPL1 gene (c.665G>A) associated with Leber congenital amaurosis type 4 in patient-derived stem cells

  • Treatment restored the AIPL1 target protein (cyclic guanosine monophosphate phosphodiesterase 6) in rod photoreceptors within retinal organoids

  • Both chemically modified RNA and dual-AAV delivery systems achieved AIPL1 rescue in photoreceptor cells

💡 This demonstrates base editing's potential for treating inherited blindness by correcting single-letter DNA changes in patient-specific tissue models.
🥉 Top 5% journal 🔗 Molecular therapy. Nucleic acids Journal Article 🗓️ Dec 17

🧠 CRISPR screen maps 150+ brain enhancers controlling Alzheimer's genes

  • Researchers functionally tested nearly 1,000 brain enhancers using CRISPR inhibition in human primary astrocytes, identifying more than 150 regulatory interactions

  • The screen revealed enhancers controlling key astrocyte functions and genes implicated in Alzheimer's disease

  • They developed EGrf, a machine learning model trained on this data, to predict regulatory interactions genome-wide with high specificity

💡 This provides the first comprehensive functional map of brain enhancers in a key glial cell type, potentially revealing new therapeutic targets for neurodegeneration.
🥇 Top 1% journal 🔗 Nature neuroscience Journal Article 🗓️ Dec 18

🩸 Engineered immune cells show 8x better tumor killing after gene editing

  • Adenine base editing of TIM3 and TIGIT genes in tumor-infiltrating lymphocytes (TILs) achieved high knockout efficiency with negligible insertion-deletion events

  • Dual-edited TILs showed improved fold-expansion during rapid expansion protocol, enhanced cytokine production, and superior serial killing of patient tumor cells

  • The edited TILs successfully infiltrated tumor spheroids and controlled patient-derived tumors in laboratory models

💡 Base editing offers a safer alternative to traditional CRISPR for engineering cancer immunotherapies, avoiding risky DNA breaks while boosting anti-tumor activity.
🎖️ Top 10% journal 🔗 Molecular therapy. Oncology Journal Article 🗓️ Dec 15

🔬 Miniature Cas12f1 editor targets both DNA strands simultaneously

  • Researchers developed base editors using Cas12f1, a miniature CRISPR protein of only 422 amino acids (much smaller than typical editors)

  • Unlike other base editors, Cas12f1 versions efficiently edited both the target DNA strand and the displaced non-target strand in distinct editing windows

  • The compact size and unique dual-strand editing profile makes it valuable for applications requiring small delivery packages

💡 This tiny editor could enable gene therapy in contexts where delivery space is limited, while offering a fundamentally different editing pattern than existing tools.
🎖️ Top 10% journal 🔗 iScience Journal Article 🗓️ Dec 16

Implications

These advances show CRISPR technology maturing beyond proof-of-concept toward clinical precision. The combination of evolved resistance, enhanced delivery methods, and unexpected regulatory mechanisms suggests we're entering a new phase where gene editing tools can be fine-tuned for specific therapeutic challenges.

Studies in this issue

Primary sources used for this newsletter.

  1. Using anti-CRISPR to continuously improve CRISPR-Cas9 gene editing in human cells
    main storybioRxiv : the preprint server for biology2025-12-19PMID 41415442
  2. Anti-CRISPR Protein AcrIIA5 May Improve the Efficiency and Safety of Prime Editing
    key findingNature communications2025-12-18PMID 41413028
  3. Base editing of both DNA strands at separate sites using a small CRISPR protein Cas12f1
    key findingiScience2025-12-16PMID 41399500
  4. Gene switches far from the gene control brain support cells linked to Alzheimer's disease
    key findingNature neuroscience2025-12-18PMID 41413662
  5. Using gene editing with lipid particles to help muscle stem cells resist injury
    key findingCell reports2025-12-18PMID 41411128
  6. Highly efficient gene editing in immune cells inside tumors using adenine base editing
    key findingMolecular therapy. Oncology2025-12-15PMID 41394272
  7. Using adenine base editing to fix inherited retinal disease mutations in patient stem cells and lab-grown retinal tissue
    key findingMolecular therapy. Nucleic acids2025-12-17PMID 41404501

Continue reading

All CRISPR Gene Editing issues